Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New acne gel put to the test in everyday life

NCT ID NCT07205107

Symptom relief Sponsor: Bausch Health Americas, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 10, 2026 · Updated 3 times

Summary

This study follows about 200 people aged 12 and older in Canada who are using a prescription gel containing clindamycin, adapalene, and benzoyl peroxide for acne. Researchers want to see how satisfied patients are, how well they stick to the treatment, and how it affects their quality of life over 20 weeks. The goal is to understand how this triple-combination treatment works in real-world settings, not just in controlled trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
clindamycin phosphate, adapalene, and benzoyl peroxide gel
What this could lead to
If successful, this study could show that this triple-combination gel is a well-liked and effective option for managing acne in everyday use.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors like how people use other skin products. It also only follows people for 20 weeks, so long-term effects aren't measured.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

200 people

The number who actually took part.

Started

Oct 2025

Finished

Aug 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Canadian routine clinical practice

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who are 12 years or older (unless minors are not permitted as per local regulations) who have been prescribed clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel as per the product monograph as part of routine clinical care for acne vulgaris but have not yet initiated treatment. The decision to prescribe clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel must be made prior to and independent of study participation. * Patients and legally authorized representatives who are willing to provide written informed consent using an Institutional Review Board (IRB) or Independent Ethics Committee (IEC)-approved Informed Consent Form (ICF) in English or French. Patients who are less than the age of consent must sign an assent for the study and a parent, or a legal guardian must sign the informed consent. * Patients who can read, understand, and communicate in English or French. Patients must also meet the following additional inclusion criterion at the time of clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel initiation in order to be eligible for enrolment in the study: * Patients have completed IRB or IEC-approved baseline ePROs (DermSat-7 and HUI2) after providing consent and prior to receiving their first dose of clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel. * Patients have initiated clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel within 5 days of signed informed consent/assent. Exclusion Criteria: * Patients who have a contraindication to clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel as per the product monograph: 1. Patients who are hypersensitive to clindamycin phosphate, to adapalene, to benzoyl peroxide or to any ingredient in the formulation or component of the container, 2. Patients with a history of regional enteritis (Crohn's disease), ulcerative colitis, or antibiotic-associated colitis, and/or 3. Pregnant women and women planning a pregnancy. * Patients who, at the time of informed consent, are clear or almost clear (Investigator Global Assessment \[IGA\] = 0 or 1) or are on current acne therapy (topical or systemic, etc.)), or undergoing procedures (e.g., laser, photodynamic therapy) that could impact study results, as per the investigator's judgement. * Patients who have any other serious and/or uncontrolled medical condition, and/or are receiving any medical therapy, that prohibits the patient from participating as per the investigator's judgement. * Patients who have whey protein-triggered acne, drug-induced acne, occupational acne, acne associated with hidradenitis suppurativa or synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome, or acne related to hyperandrogenic states including polycystic ovary syndrome (PCOS). * Patients who have conditions that mimic acne, including rosacea, folliculitis, perioral dermatitis, demodicosis. * Patients who are not willing or able to complete electronic patient reported outcomes (ePROs) using an electronic device.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acne vulgaris are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acne Acne Vulgaris

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acne vulgaris

Contacts and locations

Locations

  • CHARM Site 001

    Edmonton, Alberta, T6W 0J5, Canada

  • CHARM Site 002

    Toronto, Ontario, M5A 3R6, Canada

  • CHARM Site 003

    Winnipeg, Manitoba, R3M 3Z4, Canada

  • CHARM Site 005

    Toronto, Ontario, M4E 1R7, Canada

  • CHARM Site 006

    Pointe-Claire, Quebec, H9R 5M7, Canada

  • CHARM Site 007

    Calgary, Alberta, T2J 7E1, Canada

  • CHARM Site 008

    Montreal, Quebec, H1Y 3L1, Canada

  • CHARM Site 010

    Markham, Ontario, L3P 1X3, Canada

  • CHARM Site 011

    Richmond Hill, Ontario, L4B 1L1, Canada

  • CHARM Site 012

    Vancouver, British Columbia, V5Z 1H2, Canada

  • CHARM Site 013

    Newmarket, Ontario, L3Y 5G8, Canada

  • CHARM Site 014

    Toronto, Ontario, M4W 2N2, Canada

  • CHARM Site 015

    Ottawa, Ontario, K1V 7Z5, Canada

  • CHARM Site 016

    Toronto, Ontario, M2N 3A6, Canada

  • CHARM Site 017

    Surrey, British Columbia, V3V 0C6, Canada

  • CHARM Site 018

    Québec, Quebec, G1W 4R4, Canada

  • CHARM Site 019

    Windsor, Ontario, N8W 5L7, Canada

  • CHARM Site 021

    Hamilton, Ontario, L8P 4B4, Canada

  • CHARM Site 022

    North York, Ontario, M3B 0A7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.